Figure 4.

Sorafenib decreases the mRNA and protein expression levels of VLAs in melanoma cells with c-Kit aberration. B16BL6 cells were treated with sorafenib (0.5, 1, 5 and 10 µM). mRNA expression levels of (A) VLA-1, (B) VLA-2, (C) VLA-3, (D) VLA-4, (E) VLA-5 and (F) VLA-6 were measured via reverse transcription-quantitative PCR. Data are presented as the mean ± SD of three independent experiments. *P<0.05 vs. control. (G) Protein expression levels of VLA-1, VLA-2, VLA-3, VLA-4, VLA-5 and VLA-6 were analyzed via western blotting. β-actin was used as internal control. All determinations were made in western blotting from three different experiments. VLA, very late antigen.